TrialsgrambetaRCTs are beautiful

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

This guideline cites 2 of the 199 landmark trials in our Cardiology register.

The 2022 ESC/ERS guideline lowered the haemodynamic definition of pulmonary hypertension (mean PAP >20 mmHg) and structures pulmonary-arterial-hypertension (PAH) treatment around risk-based, upfront combination therapy. The register's landmark PAH drug trials are listed below.

PAH: targeted & combination therapy2

  • 2015AMBITION Core⁠Cardiology · PH / ACHD · Combination therapyIn 500 patients with pulmonary arterial hypertension, initial ambrisentan plus tadalafil reduced clinical-failure events compared with monotherapy.HR 0.5Read →
  • 2013SERAPHIN⁠Cardiology · PH / ACHD · Endothelin antagonistsIn 742 patients with pulmonary arterial hypertension, macitentan reduced morbidity and mortality events compared with placebo.HR 0.55Read →

Published since the guideline2

  • 2025ZENITH⁠Cardiology · PH / ACHD · Activin signallingIn 172 patients with high-risk pulmonary arterial hypertension, sotatercept reduced death, lung transplantation or heart-failure hospitalisation compared with placebo.HR 0.24Read →
  • 2023STELLAR⁠Cardiology · PH / ACHD · Activin signallingIn 323 patients with pulmonary arterial hypertension, sotatercept added to background therapy improved 6-minute walk distance compared with placebo.Read →

Cited landmark trials not yet in the register3

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2015GRIPHON

    Selexipag (oral prostacyclin-receptor agonist) in PAH.

  • 2013PATENT-1

    Riociguat (sGC stimulator) in PAH.

  • 2021PULSAR

    Sotatercept (activin-signalling inhibitor) phase-2 in PAH.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.